Exploring the directionality of 5-substitutions in a new series of 5-alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a strategy to design novel human a(3) adenosine receptor antagonists

J Med Chem. 2012 Nov 26;55(22):9654-68. doi: 10.1021/jm300899q. Epub 2012 Nov 9.

Abstract

The structure-activity relationship (SAR) of new 5-alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as antagonists of the A(3) adenosine receptor (AR) was explored with the principal aim to establish the directionality of 5-substitutions inside the orthosteric binding site of the A(3) AR. All the synthesized compounds showed affinity for the hA(3) AR from nanomolar to subnanomolar range. In particular, the most potent and selective antagonist presents an (S) α-phenylethylamino moiety at the 5 position (26, K(i) hA(3) = 0.3 nM). Using an in silico receptor-driven approach, we have determined the most favorable orientation of the substitutions at the 5 position of the pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine (PTP) scaffold, opening the possibility for further derivatizations aimed at directing the N(5) position toward the extracellular environment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenylyl Cyclases
  • Animals
  • Binding, Competitive
  • CHO Cells
  • Cricetinae
  • Drug Design*
  • Humans
  • Models, Molecular
  • Molecular Structure
  • Purinergic P1 Receptor Antagonists / chemical synthesis
  • Purinergic P1 Receptor Antagonists / pharmacology*
  • Pyrimidines / chemistry*
  • Radioligand Assay
  • Receptor, Adenosine A3 / chemistry*
  • Receptor, Adenosine A3 / metabolism
  • Structure-Activity Relationship

Substances

  • Purinergic P1 Receptor Antagonists
  • Pyrimidines
  • Receptor, Adenosine A3
  • Adenylyl Cyclases